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Abstract: In recent years, clinical research in the field of new treatments for chronic hepatitis C 
(HCV) has been devoted to developing regimens based on direct-acting antivirals (DAAs), 
with the goal of increasing treatment efficacy and improving tolerability and safety. This can 
be achieved by Peginterferon (PegIFN)-free anti-HCV regimens, as PegIFN is responsible for 
many side effects and limits treatment access due to contraindications in some patient  categories. 
Sofosbuvir (SOF) is the first compound to enter the market with IFN-free combination regimens; 
it belongs to the nucleotide inhibitors of viral polymerase NS5B and acts as a chain terminator 
during the HCV replication process, exhibiting pan-genotypic antiviral activity with a high 
barrier to resistance. Clinical trials in HCV genotype 2/3 patients have demonstrated optimal 
efficacy in HCV-2, where the combination SOF/ribavirin (Rbv) for 12 weeks resulted in .90% 
sustained virological response (SVR) rates, while HCV-3 patients with advanced liver fibrosis and 
previous failure to PegIFN plus Rbv therapy still require individualized and optimized  treatment 
strategies. Historically difficult-to-treat genotypes HCV-1, -4–6 can benefit from reduced dura-
tion of PegIFN plus SOF and Rbv, while IFN-free regimens in these patients will be based on 
SOF in combination with other DAA classes. Due to an optimal tolerability and safety profile 
with no significant drug-to-drug interactions, SOF is currently undergoing clinical trials in the 
setting of pre- and post-liver transplantation and HIV-coinfected patients, with the objective 
to address the until now unmet need for safe and efficient treatment in these populations. This 
article provides an overview of SOF features and the main clinical trials, discussing key results 
and potential future developments.
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Introduction
Chronic infection with hepatitis C virus (HCV) affects more than 170 million 
people worldwide and is a leading cause of anticipated liver-related death due to the 
 development of cirrhosis and its complications.1 In the last 10 years, standard of care 
anti-HCV treatment has been founded on the combination of Peginterferon (Peg-IFN) 
plus ribavirin (Rbv), whose main disadvantages were suboptimal rates of sustained 
virological response (SVR) in difficult-to-treat patients (HCV genotype 1–4, advanced 
liver fibrosis) and, most of all, side effects profile resulting in poor tolerability and 
treatment contraindication in some patient subsets (decompensated liver disease 
and autoimmune disorders).2 The recent availability of culture cell models provided 
deeper insight in understanding HCV life cycle and was the basis for the develop-
ment of new drugs targeting non-structural HCV proteins involved in viral replication 
process, such as NS3 and NS5A/B (Figure 1 and Table 1). Direct-acting antivirals 
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(DAAs) promised to open a new era in treating chronic HCV 
infection by increasing SVR rates, providing shortened and 
simplified regimens while also minimizing treatment-related 
side effects. First-generation NS3 protease inhibitors tel-
aprevir (TVR) and boceprevir (BOC), approved since 2011 
as the new standard of care treatment for HCV  genotype 1 
patients, have only partially met these  expectations: indeed, in 
Phase III trials and especially in larger real-life cohorts, effi-
cacy of TVR/BOC has been shown to be largely dependent 
on Peginterferon (PegIFN) plus ribavirin (Rbv) backbone 
antiviral activity, with disappointing SVR rates in difficult-
to-treat patients such as previous non-responders to dual 
therapy.3 Moreover, an unfavorable safety profile with high 
rates of side effects, especially in patients with advanced liver 
fibrosis, was the main concern with NS3 protease inhibitors, 
leading to an intensified monitoring schedule and neces-
sity for careful patient selection in order to prevent serious 
adverse events.4
In the meantime, the development of many new com-
pounds belonging to different antiviral classes is expected 
to overcome the first-generation DAAs by providing a com-
bination of all-oral, IFN-free regimens, that will also allow 
extended treatment in patients formerly contraindicated or 
intolerant to IFN-based therapies.5 This review will focus on 
sofosbuvir, formerly named GS-7977, an NS5B polymerase 
nucleotide inhibitor, whose US Food and Drug Administra-
tion (FDA) and European Medicines Agency (EMA) approv-
als have been granted at the end of 2013 and at the beginning 
of 2014, respectively.
Pharmacokinetic features
Sofosbuvir (SOF) is an HCV-specific nucleotide inhibitor 
of viral NS5B polymerase that acts as an chain terminator 
when incorporated as a substrate by RNA polymerase in the 
nascent HCV-RNA genome, leading to inhibition of viral 
replication. Due to the high conservation of the enzyme 
active site targeted by this drug class, SOF displays pan-
genotypic antiviral activity against all HCV genotypes and 
also has a high barrier to resistance.6 Cell culture replicon 
data demonstrated EC
50
 values slightly higher for HCV-
1b (110 nM) and HCV-3 (50 nM) compared to HCV-1a 
(40 nM) and HCV-2 (15 nM) replicons. SOF is administered 
once daily, via oral tablets (400 mg), with no dependence 
on food intake. It enters the hepatocytes as a prodrug of 
uridine monophosphate and is phosphorylated within the 
cells to active triphosphate form. Dephosphorylation of the 
active molecule results in the  formation of the metabolite 
GS-331007, which lacks anti-HCV activity; GS-331007 
is the main circulating metabolite of SOF and undergoes 
renal elimination. The median half-lives of SOF and 
GS-331007 are 0.4 and 27 hours,  respectively. Population 
pharmacokinetic (PK) models developed for GS-331007 
and SOF revealed that demographic variables such as age, 
sex, BMI, race, common concomitant medications, and 
cirrhosis did not influence GS-331007 or SOF exposure.7 
PK studies in patients with renal impairment demonstrated 
that dose modification of SOF is not required if creatinine 
clearance is $30 mL/minute; however, SOF safety has not 
been established in patients with severe renal impairment 
or end-stage renal disease, so dose recommendations for 
these populations cannot be provided. Concerning patients 
with hepatic impairment, PK analyses showed that cirrhosis 
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Figure 1 HCv genomic structure. After hepatocyte binding and cell internalization, HCv-RNA is released and translated into a polyprotein containing structural and non-
structural HCv proteins. NS3 serine protease and a cofactor NS4A allow for post-translational cleavage and proteolysis of the polyprotein to release NS5A and NS5B that 
start the viral replication process. inhibition of NS3, NS5A/B by different DAA classes results in impaired HCv replication.
Abbreviations: DAA, direct-acting antivirals; HCv, hepatitis C virus; RNA, ribonucleic acid.
Table 1 Main DAA targets and drug classes
Target Drug name
NS3 (protease) 
  1st wave 
 2nd wave
Telaprevir 
Boceprevir 
Simeprevir 
Faldaprevir 
Asunaprevir 
ABT-450 
vaniprevir
NS5A Daclatasvir 
Ledipasvir 
ABT-267
NS5B (polymerase) 
  Nucleotidic 
Non-nucleotidic
 
Sofosbuvir 
ABT-333
Abbreviation: DAA, direct-acting antivirals.
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had no clinically relevant effect on SOF and GS-331007 
 exposure, so no dose adjustment is recommended in patients 
with mild-to-severe hepatic impairment.
Sofosbuvir in HCV-2 and -3 patients:  
IFN-free regimens
The main goals in SOF development for historically “easy-
to-treat” genotypes were to shorten treatment duration, but 
most of all, to improve tolerability through an IFN-free 
regimen. The ELECTRON trial was the first Phase II study 
in treatment-naïve patients to explore an IFN-free arm of 
SOF/Rbv for 12 weeks compared to three arms of variable 
PegIFN duration (4/8/12 weeks), with 100% SVR in both the 
PegIFN-based and IFN-free arms.8 This was the first proof 
of concept that an all-oral, IFN-free regimen was feasible for 
HCV-2 and -3 patients; conversely, the ELECTRON trial also 
demonstrated that the key role of Rbv could not be super-
seded, as a SOF monotherapy 12-week arm reported SVR of 
60% due to a 40% virological relapse rate. Based on these 
results, the SOF/Rbv combination administered for 12 weeks 
was chosen to be further evaluated in Phase III trials. The 
 FISSION trial was an open-label, non-inferiority study enroll-
ing 499 HCV-2/3 naïve patients receiving SOF/Rbv for 12 
weeks in comparison with a standard of care arm (PegIFN/
Rbv for 24 weeks). HCV-3 patients accounted for the majority 
of the study population (72%), and 20% cirrhotic patients 
were included in the study. The trial met the non-inferiority 
endpoint, showing an overall SVR rate of 67%, although 
with large differences between the HCV-2 and -3 patients: 
indeed, when splitting SVR rates according to genotype, 
HCV-2 patients achieved 93% SVR, compared to only 56% 
in HCV-3 patients. At the multivariate analysis, liver fibrosis 
was identified as the main predictor of treatment failure only 
in HCV-3, where the presence of cirrhosis translated to SVR 
falling to 34%, while fibrosis did not influence SVR rates in 
HCV-2 patients (91%).9  Following the FISSION trial, it was 
clear that HCV-3 patients with advanced liver fibrosis could 
now be identified as the new “difficult to treat” patient group 
even with more potent regimens.
Tolerability was the main aim of the POSITRON trial, 
which evaluated the safety and efficacy of SOF/Rbv for 
12 weeks in 278 HCV-2/3 patients that were previously intol-
erant, unwilling, or contraindicated to PegIFN/Rbv. The study 
design was placebo-controlled, and similarly to the  FISSION 
trial, allowed enrollment of cirrhotic patients (18%). While 
the study confirmed overall high efficacy with 78% SVR, 
again, cure rates were extremely different according to HCV 
genotype (97% in HCV-2 versus [vs] 61% in HCV-3) and 
fell to only 21% in HCV-3 cirrhotic patients. Concerning 
safety, the combination of SOF/Rbv showed an optimal toler-
ability profile: the most frequent adverse events were fatigue 
(44%), nausea (22%), headache (21%), insomnia (19%), and 
pruritus (11%), mainly consistent with Rbv. Hemoglobin 
decline ,10 g/dL occurred in only 7% of patients (,8.5 g/dL 
in 1%), while no reduction in platelets and neutrophil values 
were reported. The  discontinuation rate due to adverse events 
was only 2%.10
The efficacy of the SOF/Rbv IFN-free combination 
in patients with a previous treatment failure to PegIFN/
Rbv was investigated in the FUSION trial, which enrolled 
201 HCV-2 and -3 patients (76% with a prior relapse) 
receiving SOF/Rbv for 12 or 16 weeks. Thirty-five percent 
of patients included in the study had compensated  cirrhosis 
and the majority enrolled were HCV-3 patients (62%). 
Overall SVR in treatment  experienced patients with SOF/
Rbv was significantly lower in the 12-week compared to 
16-week arms (50% vs 73%), with huge differences between 
HCV-2 and HCV-3 patients (86% vs 94% in HCV-2, 30% 
vs 62% in HCV-3). Cirrhosis and HCV genotype 3 were 
confirmed as predictors of  treatment failure: indeed, in the 
two treatment arms (12/16 weeks) SVR rates were respec-
tively 96%/100% in non-cirrhotic vs 60%/78% in cirrhotic 
HCV-2 patients, while in HCV-3 patients, SVR decreased 
to 37%/63% in non-cirrhotics vs 19%/61% in cirrhotics.10 
Consequently, the FUSION trial demonstrated that for 
HCV-2 the combination of SOF/Rbv provided an all-oral 
regimen with high efficacy and the possibility of shortening 
treatment to 12 weeks even in previously treatment-failure 
patients, while for HCV-3 treatment, extension to 16 weeks 
translated to higher SVR rates. However, the results were 
still largely disappointing in patients with advanced liver 
fibrosis. Results from the SOF trials in HCV-2/3 patients 
are summarized in Figure 2.
Some ongoing studies are evaluating new strategies 
to increase efficacy in HCV-3 patients: 1) the possibil-
ity of extending treatment duration to 24 weeks with the 
SOF/Rbv regimen; 2) the addition of PegIFN; and 3) the 
combination of more DAAs. According to the first strat-
egy, the VALENCE trial evaluated efficacy of a 24-week 
course of SOF/Rbv in naïve or treatment-experienced 
HCV-3 patients. The study results, recently presented to 
the AASLD  Meeting, reported overall 85% SVR12 rates; 
however, when stratifying patients according to liver staging 
and previous treatment course, SVR rates were 92%–94% 
in naïve and 87% in treatment-experienced non-cirrhotics, 
while cirrhotic patients with a previous treatment failure 
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achieved only 60% SVR.11 These data showed that these 
patients still remain difficult-to-cure even with an extended 
treatment, and consequently, could require the addition of 
an immunomodulatory drug like PegIFN or another DAA. 
Indeed, the LONESTAR-2 trial, which investigated the 
combination of SOF/PegIFN/Rbv for 12 weeks, reported 
83% SVR rates in HCV-3 cirrhotic patients previously 
treatment experienced, although limited patient numbers 
need to be confirmed in larger cohorts.12 Concerning the 
combination of more DAAs targeting different viral proteins, 
the ELECTRON trial evaluated the combination of SOF/
ledipasvir (LDV, inhibitor of NS5A)/Rbv for 12 weeks in 
a Phase II study in naïve non-cirrhotic patients, reporting 
overall 80% SVR12 rates.13
Sofosbuvir in HCV-1–6 patients:  
IFN-sparing regimens
Phase II studies in HCV-1–6 genotypes tested the possibility 
of developing an IFN-free combination for “difficult to treat” 
genotypes, or at least, to spare PegIFN administration in 
terms of limited treatment duration. The Phase IIb  open-label 
ATOMIC trial enrolled 316 naïve non-cirrhotic HCV 
genotype 1 and 16 genotype 4–6 patients receiving SOF in 
 combination with PegIFN/Rbv for 12 or 24 weeks; a third arm 
received SOF/PegIFN/Rbv for 12 weeks and then SOF ± Rbv 
for an additional 12 weeks. SVR12 rates in the three arms 
did not significantly differ, being respectively 90%, 92%, and 
91%, and no viral breakthrough was observed, so that the 
12-week duration of SOF/PegIFN/Rbv demonstrated the best 
efficacy/cost ratio in treating naïve non-cirrhotic patients.14 
An IFN-free regimen for HCV-1 patients was tested in the 
ELECTRON trial, originally enrolling only HCV-2 and -3 
patients, where a protocol amendment led to the enrollment 
of 35 HCV-1 patients (90% subtype 1a), ten previously null-
responders and 25 naïve to PegIFN/Rbv therapy, receiving an 
IFN-free regimen of SOF/Rbv for 12 weeks. The two patient 
groups showed dramatically different SVR rates, as only 
10% of null responders achieved SVR, compared to 84% 
of naïve patients, with relapse rates being respectively 84% 
and 26%.8 This was the demonstration that to achieve high 
SVR rates in HCV-1 patients, SOF needs to be combined 
with PegIFN and Rbv.
NEUTRINO was the first SOF Phase III trial in 327 HCV 
genotype 1,4–6 naïve patients with the aim to evaluate the 
safety and efficacy of the combination regimen SOF/PegIFN/
Rbv for 12 weeks. Patient baseline demography included 
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Figure 2 Sofosbuvir trials in HCv-2 and -3 patients.
Abbreviations: HCv, hepatitis C virus; iFN, interferon; Rbv, ribavirin; SOF, sofosbuvir; SvR, sustained virological response.
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89% HCV-1 (69% subtype 1a), 9% HCV-4, and 2% HCV-5,6 
patients; IL28B non-CC genotype accounted for the majority 
(71%) of patients. NEUTRINO allowed enrollment of cir-
rhotic patients, who represented 17% of study population.
The combination of SOF/PegIFN/Rbv for 12 weeks dem-
onstrated high rates of on-treatment response, with 91% of 
patients achieving HCV-RNA undetectability at week 2 and 
99% at week 4, which resulted in an overall SVR rate of 90%. 
When stratifying patients according to HCV genotype, SVR 
rates were 89% in HCV-1, 96% in HCV-4, and 100% in HCV-
5,6 (despite the small number of HCV-4–6 patients included). 
HCV subtype 1a achieved higher SVR rates than 1b (92% vs 
82%). At multivariate analysis, the IL28B  genotype non-CC 
and cirrhosis were found to be predictors of treatment failure: 
indeed SVR rates were 87% in non-CC vs 98% in CC patients 
(P=0.006, OR: 7.989), while cirrhotic patients achieved overall 
80% SVR vs 92% in non-cirrhotics (P=0.002, OR: 3.924). 
Viral kinetics on-treatment did not significantly differ in cir-
rhotics vs non-cirrhotic patients, all patients achieved high 
on-treatment response rates; relapse accounted for all treatment 
failures, as no viral breakthrough was observed. Concerning 
safety profile, the most common side effects reported were 
fatigue (59%), headache (36%), nausea (34%), and insomnia 
(25%), which are mainly  consistent with Rbv or PegIFN safety 
profiles. Anemia with Hb ,10 g/dL was observed in 23%, 
while only 2% of patients had Hb ,8.5 g/dL. Discontinuation 
rates due to adverse events were lower than 2%.9
Results from the SOF Phase III trials are summarized 
in Table 2.
SOF in combination  
with other DAAs: IFN-free  
regimens for HCV 1–4
The possibility of developing an IFN-free regimen for 
 difficult-to-treat genotypes requires the combination of 
different DAA classes to provide high antiviral efficacy as 
well as a high barrier to resistance. According to these fea-
tures, the ideal regimen could combine nucleotide inhibitors 
of NS5B such as SOF, compounds with the highest resistance 
barrier, plus NS5A or NS3 inhibitors that are characterized 
by the strongest viral suppression. The first combination of 
SOF plus NS5A inhibitors was evaluated in a Phase II study in 
treatment-naïve non-cirrhotic HCV-1 patients who received 
SOF in combination with daclatasvir (DCV) 60 mg QD ± 
Rbv for 12 or 24 weeks, reporting 100% SVR in all treat-
ment arms. In the same study, a cohort of 41 patients with a 
previous treatment failure to protease inhibitors BOC or TVR 
were treated with SOF/DCV ± Rbv for 24 weeks, showing 
100% SVR rates as well.15 This study confirmed that the 
possible emergence of resistance-associated variants (RAVs) 
to protease inhibitors lacks cross-resistance with other DAA 
classes and could be efficiently cured by more potent drug 
combinations. Another promising IFN-free regimen is SOF 
in combination with the NS5A inhibitor LDV 90 mg QD ± 
Rbv, which has been evaluated by the LONESTAR trial in 
HCV-1 naïve and TVR/BOC-experienced patients: the study 
demonstrated that 8 weeks of SOF/LDV were sufficient to 
achieve respectively 100% and 95% SVR rates with or with-
out Rbv. In the TVR/BOC-experienced population, where 
55% of patients had cirrhosis, SVR rates were respectively 
100% and 95% in arms receiving a 12-week treatment course 
with or without Rbv (Figure 3). Resistance analysis showed 
S282T NS5B mutation and multiple NS5A RAVs detected 
at relapse in one patient receiving SOF/LDV for 8 weeks; 
the patient subsequently achieved SVR12 after retreatment 
with SOF/LDV + Rbv. R155K was the most common RAV 
in PI-experienced patients; however, all patients with RAVs 
achieved SVR.16 The ELECTRON Phase II study is cur-
rently evaluating the efficacy of SOF/LDV ± Rbv in addi-
tional cohorts, including HCV-1 cirrhotics that were prior 
Table 2 Summary of sofosbuvir Phase iii trials
Trial HCV  
genotype
Patient population 
(% cirrhosis)
Treatment  
status
Regimen Key messages
FiSSiON 2–3 499 (20%) Naïve SOF + Rbv 12 w •   SOF + Rbv high overall efficacy
•   Lower SvR rates in HCv-3 cirrhotics
POSiTRON 2–3 278 (15%) iFN intolerant,  
ineligible/unwilling
SOF + Rbv 12 w •   Optimal tolerability, low side effects
FUSiON 2–3 201 (34%) iFN experienced SOF + Rbv 12/16 w •   Suboptimal SvR in HCv-3 cirrhotics
•   Better SvR rates in HCv-3 with  
extended 16-week course
NEUTRiNO 1,4–6 327 (17%) Naïve SOF + PegiFN + Rbv  
12 w
•   High efficacy (.90%) across all  
genotypes
Abbreviations: HCv, hepatitis C virus; iFN, interferon; PegiFN, Peginterferon; Rbv, ribavirin; SOF, sofosbuvir; SvR, sustained virological response; w, weeks.
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null-responders to dual therapy. Preliminary efficacy results 
reported respectively 89% and 80% SVR4 rates following a 
12-week treatment course with or without Rbv.13
The combination of 12 or 24 weeks of SOF plus the NS3 
inhibitor simeprevir was evaluated by the COSMOS Phase II 
study, where an overall 93% SVR12 rate in non-cirrhotic 
HCV-1 previous null-responder to PegIFN/Rbv was obtained. 
Interim analysis of a second cohort including cirrhotic HCV-1 
naïve and null-responder patients showed 100% SVR4 with 
the 12-week regimen.17
Concerning only the HCV-4 patient population, a pilot 
study evaluated the IFN-free combination of SOF/Rbv for 
12 or 24 weeks in HCV-4 treatment-naïve or -experienced 
patients of Egyptian ancestry, showing respectively 79% 
SVR12 in naïve and 59% in experienced patients in the 
12-week arms, while SVR12 for the 24-week regimens are 
still pending.18
Resistance
In all Phase III studies, SOF confirmed its potent antivi-
ral activity and high resistance barrier, as 99% of patients 
achieved HCV-RNA undetectability by treatment week 4 and 
all virological failures were due to relapse. S282T has been 
identified as the primary mutation leading to a 4- to 24-fold 
decrease in  susceptibility to SOF for all tested genotypes. In the 
 ELECTRON Phase II trial, the S282T substitution was detected 
in a single HCV-2 subject who received SOF monotherapy for 
12 weeks and relapsed 4 weeks after the end of treatment. The 
sample had a mean 13.5-fold reduced susceptibility to SOF; 
however, the mutation was no longer detectable 12 weeks after 
the end of treatment by next-generation sequencing analysis.8 
In Phase III studies, S282T mutation was not detected either 
in baseline samples or at the time of relapse in any patient. 
Other treatment-emergent NS5B substitutions (L159F, E341D, 
L320F) were frequently observed in patients relapsing to 
SOF-based regimens; however, none were associated with a 
phenotypic change in SOF or Rbv susceptibility.9,10
Predictors of treatment outcome  
with SOF-based regimens
In the era of PegIFN plus Rbv dual therapy, many host  factors 
have been identified as predictors affecting treatment outcome 
in addition to viral genotype, such as sex, age, ethnicity, 
 obesity, insulin-resistance, coinfections (HIV), and liver 
fibrosis stage.19 More recently, the discovery of the single 
nucleotide polymorphism (SNP) rs12979860 near the inter-
leukin 28B (IL28B) region as the strongest baseline predictor 
of SVR to PegIFN plus Rbv in HCV-1,4 and, to a lesser extent, 
in HCV-2,3, represented a turning point in treatment outcome 
prediction, leading to better treatment individualization.20
This scenario is expected to gradually change when mov-
ing to DAAs, as the increased viral potency will eventually 
overcome the role of some host predictors, which affect 
treatment outcome in a relevant manner only when con-
sidering regimens with suboptimal efficacy. This was only 
partially true with telaprevir and boceprevir, whose antiviral 
efficacies were still driven by that of the PegIFN plus Rbv 
backbone; instead, when considering SOF-based regimens, 
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Figure 3 Sofosbuvir + ledipasvir ± ribavirin in HCv-1 patients: the LONESTAR trial.
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a retrospective analysis of registration trials demonstrated that 
the historically negative predictors of response to IFN-based 
regimens did not significantly affect SVR rates. Indeed, when 
analyzing patients by the presence/absence of historically 
negative predictors such as cirrhosis, age $65 years, obesity, 
IL28B TT genotype, diabetes, black race, and high baseline 
viral load ($107 IU/mL), SVR rates were independent of all 
predictors except for cirrhosis in HCV-3 patients, which has 
been already discussed above.21
Drug-to-drug interactions (DDIs)
SOF is a substrate of drug transporters P-gp and breast cancer 
resistance protein (BCRP), whereas this is not true for the 
metabolite GS-331007. Co- administration studies showed no 
clinically significant interaction with cyclosporine A (CsA) or 
tacrolimus (TAC). High-dose CsA increased systemic SOF 
exposure (AUC), with ∼10% increase in total drug-related 
material with no increase in nucleotide metabolite. Based 
on these results, CsA or TAC can be co-administered with 
SOF without dose modification.22 No clinically significant 
DDIs were observed between SOF and the following drugs: 
tenofovir, efavirenz, darunavir/ritonavir, raltegravir, emtric-
itabine, and rilpivirine, so co-administration in HIV-infected 
patients is feasible. Also, methadone did not display clinically 
relevant DDIs with SOF.23
Finally, potential DDIs between SOF and hormonal oral 
contraceptives have also been evaluated: co-administration 
with norgestimate/ethinyl estradiol was safe and well-
tolerated, without significant alterations in PK data.24 Based 
on these observations, no loss in contraceptive efficacy is 
expected and concomitant use with SOF is allowed.
SOF in special populations:  
orthotopic liver transplantation  
(OLT) and HIV
HCV graft reinfection occurs in all HCV-RNA positive 
patients at the time of liver transplantation and is  associated 
with reduced survival due to disease recurrence, and is 
characterized by rapid fibrosis progression and results in 
poor graft outcome. Anti-HCV treatment in the pre- and 
post-transplant phase has always been hampered by several 
limitations with PegIFN-based regimens: treatment exclu-
sion because of hepatic decompensation and risk of life-
threatening infections in the pre-transplant, while, in the 
post-transplant, difficult treatment management due to drug 
interactions with immunosuppressants and high rates of side 
effects that translate to reduced efficacy. In this scenario, 
development of IFN-free regimens with high tolerability and 
efficacy without DDIs would translate to extending treatment 
access in pre- and post-OLT patients, consequently prevent-
ing HCV recurrence and disease progression.
Results from a multicenter study in 61 OLT candidates for 
hepatocellular carcinoma (HCC) and HCV-related cirrhosis 
showed prevention of graft reinfection in 64% of patients 
treated with SOF/Rbv up to 48 weeks before liver transplanta-
tion and testing HCV-RNA below the limit of quantification 
(LLOQ) at the time of liver transplant. The strongest predictor 
of post-transplant virological response was the number of 
consecutive days of HCV-RNA undetectability.25 It has to be 
pointed out that the study was conducted in a selected patient 
population with Child score #7, which is consequently not 
entirely representative of the HCV pre-transplant patient 
population. More studies are needed to evaluate the safety 
and efficacy of SOF-based regimens, especially in the set-
ting of more severe hepatic decompensation and end-stage 
liver disease.
Concerning antiviral treatment in post-OLT, preliminary 
results with SOF/Rbv treatment for 24 weeks in patients 
with recurrent HCV hepatitis after liver transplantation have 
been recently presented to the AASLD Meeting: in a small 
patient population (40 patients included, mainly HCV-1a or 
1b, 63% with bridging fibrosis or cirrhosis), treatment was 
safe and well-tolerated. No significant interactions with com-
mon immunosuppressants were observed and no episodes 
of rejection occurred. Overall SVR4 rates were 77%, while 
SVR12 efficacy data are still awaited.26
Preliminary data are also available on compassionate 
SOF use in 44 OLT patients with severe HCV recurrence: 
treatment with SOF/Rbv ± PegIFN for #48 weeks showed 
significant improvement in liver function tests and clinical 
outcomes such as reduction in episodes of decompensa-
tion and hepatic encephalopathy in 64% of patients. After 
24 weeks of treatment, 64%–83% of patients achieved HCV-
RNA undetectability and SVR12 rates ranged between 50% 
and 60%. High mortality rates (25%), mainly due to disease 
progression, were the result of treating a patient population 
with severe HCV recurrence, with 47% with a histological 
diagnosis of fibrosing cholestatic hepatitis, which is typically 
characterized by poor short-term outcome.27
HIV–HCV coinfected patients represent another 
urgent-to-treat patient population, as HIV coinfection is 
a known predictor of faster fibrosis progression and poor 
long-term outcome. The PHOTON-1 study in 182 HCV-1–3 
patients receiving SOF/Rbv for 24 (HCV-1) or 12 weeks 
(HCV-2/3) showed overall 76%, 88%, and 67% SVR12 
rates,  respectively. No significant changes in CD4 T cell 
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count were reported and treatment was well-tolerated, with 
no interactions between SOF and multiple different antiret-
roviral regimens.28 More trials are expected to confirm these 
data in larger populations.
Conclusion
The development of IFN-free or sparing regimens represents 
a breakthrough novelty in the history of anti-HCV treatment. 
The next few years are expected to radically modify chronic 
hepatitis C scenarios, as access to safe and potent therapies will 
translate to the simplification of treatment management with 
the possibility to include formerly PegIFN- contraindicated 
patient populations. Increased treatment efficacy will also 
revolutionize clinicians’ approach to patient counseling, as 
previous models for treatment individualization and outcome 
predictors with PegIFN plus Rbv will be mostly overcome. 
SOF will be one of the first DAAs in this era (Table 3) and 
its commercialization will be the key moment to address 
some open questions with these new regimens, as the huge 
raise in treatment costs will represent the first problem to 
solve for national health care services. Consequently, afford-
ability could be the driving force for the development of new 
strategies in treatment individualization, where some “old” 
but “sufficiently effective” regimens could still represent an 
important option in selected patient populations.
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 iFN sparing 
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 iFN free 
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2014 
2015 (off-label) 
2015 
2014 (off-label)
HCv-2/3
 iFN free 
  • SOF + Rbv 12 weeks (HCv-3: 16/24 weeks) 
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2014 
2014
HCv-4 
  iFN sparing 
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2014 
2014 (off-label)
Abbreviations: DCv, daclatasvir; FDA, US Food and Drug Administration; HCv, 
hepatitis C virus; LDv, ledipasvir; PegiFN, Peginterferon; Rbv, ribavirin; SOF, 
sofosbuvir; SMv, simeprevir.
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